Global Pneumococcal 13-valent Conjugate Vaccine Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030

Page: 72

Published Date: 28 Oct 2024

Category: Pharma & Healthcare

PDF Download

Get FREE Sample

Customize Request

Description
Table of Contents
Table of Figures
Research Methodology
Companies Mentioned
Related Reports
Product Tags

Description

The Pneumococcal 13-valent Conjugate Vaccine (PCV13) is a vaccine designed to protect against infections caused by Streptococcus pneumoniae bacteria, commonly known as pneumococcus. It targets 13 specific strains (or serotypes) of the bacteria, which are responsible for severe illnesses such as pneumonia, meningitis, and sepsis. By preventing these infections, PCV13 is particularly important in protecting young children, and people with weakened immune systems.

According to our (Global Info Research) latest study, the global Pneumococcal 13-valent Conjugate Vaccine market size was valued at US$ million in 2023 and is forecast to a readjusted size of USD million by 2030 with a CAGR of %during review period.

This report is a detailed and comprehensive analysis for global Pneumococcal 13-valent Conjugate Vaccine market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2024, are provided.

Key Features:
Global Pneumococcal 13-valent Conjugate Vaccine market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2019-2030
Global Pneumococcal 13-valent Conjugate Vaccine market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2019-2030
Global Pneumococcal 13-valent Conjugate Vaccine market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2019-2030
Global Pneumococcal 13-valent Conjugate Vaccine market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2019-2024
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Pneumococcal 13-valent Conjugate Vaccine
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Pneumococcal 13-valent Conjugate Vaccine market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Pfizer, Walvax, BIOKANGTAI, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Market Segmentation
Pneumococcal 13-valent Conjugate Vaccine market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type
    0.5ml
    Other

Market segment by Application
    Hospital
    Clinic

Major players covered
    Pfizer
    Walvax
    BIOKANGTAI

Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Pneumococcal 13-valent Conjugate Vaccine product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Pneumococcal 13-valent Conjugate Vaccine, with price, sales quantity, revenue, and global market share of Pneumococcal 13-valent Conjugate Vaccine from 2019 to 2024.
Chapter 3, the Pneumococcal 13-valent Conjugate Vaccine competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Pneumococcal 13-valent Conjugate Vaccine breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2019 to 2030.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2019 to 2030.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2019 to 2024.and Pneumococcal 13-valent Conjugate Vaccine market forecast, by regions, by Type, and by Application, with sales and revenue, from 2025 to 2030.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Pneumococcal 13-valent Conjugate Vaccine.
Chapter 14 and 15, to describe Pneumococcal 13-valent Conjugate Vaccine sales channel, distributors, customers, research findings and conclusion.

Table of Contents

1 Market Overview
    1.1 Product Overview and Scope
    1.2 Market Estimation Caveats and Base Year
    1.3 Market Analysis by Type
        1.3.1 Overview: Global Pneumococcal 13-valent Conjugate Vaccine Consumption Value by Type: 2019 Versus 2023 Versus 2030
        1.3.2 0.5ml
        1.3.3 Other
    1.4 Market Analysis by Application
        1.4.1 Overview: Global Pneumococcal 13-valent Conjugate Vaccine Consumption Value by Application: 2019 Versus 2023 Versus 2030
        1.4.2 Hospital
        1.4.3 Clinic
    1.5 Global Pneumococcal 13-valent Conjugate Vaccine Market Size & Forecast
        1.5.1 Global Pneumococcal 13-valent Conjugate Vaccine Consumption Value (2019 & 2023 & 2030)
        1.5.2 Global Pneumococcal 13-valent Conjugate Vaccine Sales Quantity (2019-2030)
        1.5.3 Global Pneumococcal 13-valent Conjugate Vaccine Average Price (2019-2030)

2 Manufacturers Profiles
    2.1 Pfizer
        2.1.1 Pfizer Details
        2.1.2 Pfizer Major Business
        2.1.3 Pfizer Pneumococcal 13-valent Conjugate Vaccine Product and Services
        2.1.4 Pfizer Pneumococcal 13-valent Conjugate Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
        2.1.5 Pfizer Recent Developments/Updates
    2.2 Walvax
        2.2.1 Walvax Details
        2.2.2 Walvax Major Business
        2.2.3 Walvax Pneumococcal 13-valent Conjugate Vaccine Product and Services
        2.2.4 Walvax Pneumococcal 13-valent Conjugate Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
        2.2.5 Walvax Recent Developments/Updates
    2.3 BIOKANGTAI
        2.3.1 BIOKANGTAI Details
        2.3.2 BIOKANGTAI Major Business
        2.3.3 BIOKANGTAI Pneumococcal 13-valent Conjugate Vaccine Product and Services
        2.3.4 BIOKANGTAI Pneumococcal 13-valent Conjugate Vaccine Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2019-2024)
        2.3.5 BIOKANGTAI Recent Developments/Updates

3 Competitive Environment: Pneumococcal 13-valent Conjugate Vaccine by Manufacturer
    3.1 Global Pneumococcal 13-valent Conjugate Vaccine Sales Quantity by Manufacturer (2019-2024)
    3.2 Global Pneumococcal 13-valent Conjugate Vaccine Revenue by Manufacturer (2019-2024)
    3.3 Global Pneumococcal 13-valent Conjugate Vaccine Average Price by Manufacturer (2019-2024)
    3.4 Market Share Analysis (2023)
        3.4.1 Producer Shipments of Pneumococcal 13-valent Conjugate Vaccine by Manufacturer Revenue ($MM) and Market Share (%): 2023
        3.4.2 Top 3 Pneumococcal 13-valent Conjugate Vaccine Manufacturer Market Share in 2023
        3.4.3 Top 6 Pneumococcal 13-valent Conjugate Vaccine Manufacturer Market Share in 2023
    3.5 Pneumococcal 13-valent Conjugate Vaccine Market: Overall Company Footprint Analysis
        3.5.1 Pneumococcal 13-valent Conjugate Vaccine Market: Region Footprint
        3.5.2 Pneumococcal 13-valent Conjugate Vaccine Market: Company Product Type Footprint
        3.5.3 Pneumococcal 13-valent Conjugate Vaccine Market: Company Product Application Footprint
    3.6 New Market Entrants and Barriers to Market Entry
    3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region
    4.1 Global Pneumococcal 13-valent Conjugate Vaccine Market Size by Region
        4.1.1 Global Pneumococcal 13-valent Conjugate Vaccine Sales Quantity by Region (2019-2030)
        4.1.2 Global Pneumococcal 13-valent Conjugate Vaccine Consumption Value by Region (2019-2030)
        4.1.3 Global Pneumococcal 13-valent Conjugate Vaccine Average Price by Region (2019-2030)
    4.2 North America Pneumococcal 13-valent Conjugate Vaccine Consumption Value (2019-2030)
    4.3 Europe Pneumococcal 13-valent Conjugate Vaccine Consumption Value (2019-2030)
    4.4 Asia-Pacific Pneumococcal 13-valent Conjugate Vaccine Consumption Value (2019-2030)
    4.5 South America Pneumococcal 13-valent Conjugate Vaccine Consumption Value (2019-2030)
    4.6 Middle East & Africa Pneumococcal 13-valent Conjugate Vaccine Consumption Value (2019-2030)

5 Market Segment by Type
    5.1 Global Pneumococcal 13-valent Conjugate Vaccine Sales Quantity by Type (2019-2030)
    5.2 Global Pneumococcal 13-valent Conjugate Vaccine Consumption Value by Type (2019-2030)
    5.3 Global Pneumococcal 13-valent Conjugate Vaccine Average Price by Type (2019-2030)

6 Market Segment by Application
    6.1 Global Pneumococcal 13-valent Conjugate Vaccine Sales Quantity by Application (2019-2030)
    6.2 Global Pneumococcal 13-valent Conjugate Vaccine Consumption Value by Application (2019-2030)
    6.3 Global Pneumococcal 13-valent Conjugate Vaccine Average Price by Application (2019-2030)

7 North America
    7.1 North America Pneumococcal 13-valent Conjugate Vaccine Sales Quantity by Type (2019-2030)
    7.2 North America Pneumococcal 13-valent Conjugate Vaccine Sales Quantity by Application (2019-2030)
    7.3 North America Pneumococcal 13-valent Conjugate Vaccine Market Size by Country
        7.3.1 North America Pneumococcal 13-valent Conjugate Vaccine Sales Quantity by Country (2019-2030)
        7.3.2 North America Pneumococcal 13-valent Conjugate Vaccine Consumption Value by Country (2019-2030)
        7.3.3 United States Market Size and Forecast (2019-2030)
        7.3.4 Canada Market Size and Forecast (2019-2030)
        7.3.5 Mexico Market Size and Forecast (2019-2030)

8 Europe
    8.1 Europe Pneumococcal 13-valent Conjugate Vaccine Sales Quantity by Type (2019-2030)
    8.2 Europe Pneumococcal 13-valent Conjugate Vaccine Sales Quantity by Application (2019-2030)
    8.3 Europe Pneumococcal 13-valent Conjugate Vaccine Market Size by Country
        8.3.1 Europe Pneumococcal 13-valent Conjugate Vaccine Sales Quantity by Country (2019-2030)
        8.3.2 Europe Pneumococcal 13-valent Conjugate Vaccine Consumption Value by Country (2019-2030)
        8.3.3 Germany Market Size and Forecast (2019-2030)
        8.3.4 France Market Size and Forecast (2019-2030)
        8.3.5 United Kingdom Market Size and Forecast (2019-2030)
        8.3.6 Russia Market Size and Forecast (2019-2030)
        8.3.7 Italy Market Size and Forecast (2019-2030)

9 Asia-Pacific
    9.1 Asia-Pacific Pneumococcal 13-valent Conjugate Vaccine Sales Quantity by Type (2019-2030)
    9.2 Asia-Pacific Pneumococcal 13-valent Conjugate Vaccine Sales Quantity by Application (2019-2030)
    9.3 Asia-Pacific Pneumococcal 13-valent Conjugate Vaccine Market Size by Region
        9.3.1 Asia-Pacific Pneumococcal 13-valent Conjugate Vaccine Sales Quantity by Region (2019-2030)
        9.3.2 Asia-Pacific Pneumococcal 13-valent Conjugate Vaccine Consumption Value by Region (2019-2030)
        9.3.3 China Market Size and Forecast (2019-2030)
        9.3.4 Japan Market Size and Forecast (2019-2030)
        9.3.5 South Korea Market Size and Forecast (2019-2030)
        9.3.6 India Market Size and Forecast (2019-2030)
        9.3.7 Southeast Asia Market Size and Forecast (2019-2030)
        9.3.8 Australia Market Size and Forecast (2019-2030)

10 South America
    10.1 South America Pneumococcal 13-valent Conjugate Vaccine Sales Quantity by Type (2019-2030)
    10.2 South America Pneumococcal 13-valent Conjugate Vaccine Sales Quantity by Application (2019-2030)
    10.3 South America Pneumococcal 13-valent Conjugate Vaccine Market Size by Country
        10.3.1 South America Pneumococcal 13-valent Conjugate Vaccine Sales Quantity by Country (2019-2030)
        10.3.2 South America Pneumococcal 13-valent Conjugate Vaccine Consumption Value by Country (2019-2030)
        10.3.3 Brazil Market Size and Forecast (2019-2030)
        10.3.4 Argentina Market Size and Forecast (2019-2030)

11 Middle East & Africa
    11.1 Middle East & Africa Pneumococcal 13-valent Conjugate Vaccine Sales Quantity by Type (2019-2030)
    11.2 Middle East & Africa Pneumococcal 13-valent Conjugate Vaccine Sales Quantity by Application (2019-2030)
    11.3 Middle East & Africa Pneumococcal 13-valent Conjugate Vaccine Market Size by Country
        11.3.1 Middle East & Africa Pneumococcal 13-valent Conjugate Vaccine Sales Quantity by Country (2019-2030)
        11.3.2 Middle East & Africa Pneumococcal 13-valent Conjugate Vaccine Consumption Value by Country (2019-2030)
        11.3.3 Turkey Market Size and Forecast (2019-2030)
        11.3.4 Egypt Market Size and Forecast (2019-2030)
        11.3.5 Saudi Arabia Market Size and Forecast (2019-2030)
        11.3.6 South Africa Market Size and Forecast (2019-2030)

12 Market Dynamics
    12.1 Pneumococcal 13-valent Conjugate Vaccine Market Drivers
    12.2 Pneumococcal 13-valent Conjugate Vaccine Market Restraints
    12.3 Pneumococcal 13-valent Conjugate Vaccine Trends Analysis
    12.4 Porters Five Forces Analysis
        12.4.1 Threat of New Entrants
        12.4.2 Bargaining Power of Suppliers
        12.4.3 Bargaining Power of Buyers
        12.4.4 Threat of Substitutes
        12.4.5 Competitive Rivalry

13 Raw Material and Industry Chain
    13.1 Raw Material of Pneumococcal 13-valent Conjugate Vaccine and Key Manufacturers
    13.2 Manufacturing Costs Percentage of Pneumococcal 13-valent Conjugate Vaccine
    13.3 Pneumococcal 13-valent Conjugate Vaccine Production Process
    13.4 Industry Value Chain Analysis

14 Shipments by Distribution Channel
    14.1 Sales Channel
        14.1.1 Direct to End-User
        14.1.2 Distributors
    14.2 Pneumococcal 13-valent Conjugate Vaccine Typical Distributors
    14.3 Pneumococcal 13-valent Conjugate Vaccine Typical Customers

15 Research Findings and Conclusion

16 Appendix
    16.1 Methodology
    16.2 Research Process and Data Source
    16.3 Disclaimer

Table of Figures

List of Tables
 Table 1. Global Pneumococcal 13-valent Conjugate Vaccine Consumption Value by Type, (USD Million), 2019 & 2023 & 2030
 Table 2. Global Pneumococcal 13-valent Conjugate Vaccine Consumption Value by Application, (USD Million), 2019 & 2023 & 2030
 Table 3. Pfizer Basic Information, Manufacturing Base and Competitors
 Table 4. Pfizer Major Business
 Table 5. Pfizer Pneumococcal 13-valent Conjugate Vaccine Product and Services
 Table 6. Pfizer Pneumococcal 13-valent Conjugate Vaccine Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
 Table 7. Pfizer Recent Developments/Updates
 Table 8. Walvax Basic Information, Manufacturing Base and Competitors
 Table 9. Walvax Major Business
 Table 10. Walvax Pneumococcal 13-valent Conjugate Vaccine Product and Services
 Table 11. Walvax Pneumococcal 13-valent Conjugate Vaccine Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
 Table 12. Walvax Recent Developments/Updates
 Table 13. BIOKANGTAI Basic Information, Manufacturing Base and Competitors
 Table 14. BIOKANGTAI Major Business
 Table 15. BIOKANGTAI Pneumococcal 13-valent Conjugate Vaccine Product and Services
 Table 16. BIOKANGTAI Pneumococcal 13-valent Conjugate Vaccine Sales Quantity (K Units), Average Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019-2024)
 Table 17. BIOKANGTAI Recent Developments/Updates
 Table 18. Global Pneumococcal 13-valent Conjugate Vaccine Sales Quantity by Manufacturer (2019-2024) & (K Units)
 Table 19. Global Pneumococcal 13-valent Conjugate Vaccine Revenue by Manufacturer (2019-2024) & (USD Million)
 Table 20. Global Pneumococcal 13-valent Conjugate Vaccine Average Price by Manufacturer (2019-2024) & (US$/Unit)
 Table 21. Market Position of Manufacturers in Pneumococcal 13-valent Conjugate Vaccine, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2023
 Table 22. Head Office and Pneumococcal 13-valent Conjugate Vaccine Production Site of Key Manufacturer
 Table 23. Pneumococcal 13-valent Conjugate Vaccine Market: Company Product Type Footprint
 Table 24. Pneumococcal 13-valent Conjugate Vaccine Market: Company Product Application Footprint
 Table 25. Pneumococcal 13-valent Conjugate Vaccine New Market Entrants and Barriers to Market Entry
 Table 26. Pneumococcal 13-valent Conjugate Vaccine Mergers, Acquisition, Agreements, and Collaborations
 Table 27. Global Pneumococcal 13-valent Conjugate Vaccine Consumption Value by Region (2019-2023-2030) & (USD Million) & CAGR
 Table 28. Global Pneumococcal 13-valent Conjugate Vaccine Sales Quantity by Region (2019-2024) & (K Units)
 Table 29. Global Pneumococcal 13-valent Conjugate Vaccine Sales Quantity by Region (2025-2030) & (K Units)
 Table 30. Global Pneumococcal 13-valent Conjugate Vaccine Consumption Value by Region (2019-2024) & (USD Million)
 Table 31. Global Pneumococcal 13-valent Conjugate Vaccine Consumption Value by Region (2025-2030) & (USD Million)
 Table 32. Global Pneumococcal 13-valent Conjugate Vaccine Average Price by Region (2019-2024) & (US$/Unit)
 Table 33. Global Pneumococcal 13-valent Conjugate Vaccine Average Price by Region (2025-2030) & (US$/Unit)
 Table 34. Global Pneumococcal 13-valent Conjugate Vaccine Sales Quantity by Type (2019-2024) & (K Units)
 Table 35. Global Pneumococcal 13-valent Conjugate Vaccine Sales Quantity by Type (2025-2030) & (K Units)
 Table 36. Global Pneumococcal 13-valent Conjugate Vaccine Consumption Value by Type (2019-2024) & (USD Million)
 Table 37. Global Pneumococcal 13-valent Conjugate Vaccine Consumption Value by Type (2025-2030) & (USD Million)
 Table 38. Global Pneumococcal 13-valent Conjugate Vaccine Average Price by Type (2019-2024) & (US$/Unit)
 Table 39. Global Pneumococcal 13-valent Conjugate Vaccine Average Price by Type (2025-2030) & (US$/Unit)
 Table 40. Global Pneumococcal 13-valent Conjugate Vaccine Sales Quantity by Application (2019-2024) & (K Units)
 Table 41. Global Pneumococcal 13-valent Conjugate Vaccine Sales Quantity by Application (2025-2030) & (K Units)
 Table 42. Global Pneumococcal 13-valent Conjugate Vaccine Consumption Value by Application (2019-2024) & (USD Million)
 Table 43. Global Pneumococcal 13-valent Conjugate Vaccine Consumption Value by Application (2025-2030) & (USD Million)
 Table 44. Global Pneumococcal 13-valent Conjugate Vaccine Average Price by Application (2019-2024) & (US$/Unit)
 Table 45. Global Pneumococcal 13-valent Conjugate Vaccine Average Price by Application (2025-2030) & (US$/Unit)
 Table 46. North America Pneumococcal 13-valent Conjugate Vaccine Sales Quantity by Type (2019-2024) & (K Units)
 Table 47. North America Pneumococcal 13-valent Conjugate Vaccine Sales Quantity by Type (2025-2030) & (K Units)
 Table 48. North America Pneumococcal 13-valent Conjugate Vaccine Sales Quantity by Application (2019-2024) & (K Units)
 Table 49. North America Pneumococcal 13-valent Conjugate Vaccine Sales Quantity by Application (2025-2030) & (K Units)
 Table 50. North America Pneumococcal 13-valent Conjugate Vaccine Sales Quantity by Country (2019-2024) & (K Units)
 Table 51. North America Pneumococcal 13-valent Conjugate Vaccine Sales Quantity by Country (2025-2030) & (K Units)
 Table 52. North America Pneumococcal 13-valent Conjugate Vaccine Consumption Value by Country (2019-2024) & (USD Million)
 Table 53. North America Pneumococcal 13-valent Conjugate Vaccine Consumption Value by Country (2025-2030) & (USD Million)
 Table 54. Europe Pneumococcal 13-valent Conjugate Vaccine Sales Quantity by Type (2019-2024) & (K Units)
 Table 55. Europe Pneumococcal 13-valent Conjugate Vaccine Sales Quantity by Type (2025-2030) & (K Units)
 Table 56. Europe Pneumococcal 13-valent Conjugate Vaccine Sales Quantity by Application (2019-2024) & (K Units)
 Table 57. Europe Pneumococcal 13-valent Conjugate Vaccine Sales Quantity by Application (2025-2030) & (K Units)
 Table 58. Europe Pneumococcal 13-valent Conjugate Vaccine Sales Quantity by Country (2019-2024) & (K Units)
 Table 59. Europe Pneumococcal 13-valent Conjugate Vaccine Sales Quantity by Country (2025-2030) & (K Units)
 Table 60. Europe Pneumococcal 13-valent Conjugate Vaccine Consumption Value by Country (2019-2024) & (USD Million)
 Table 61. Europe Pneumococcal 13-valent Conjugate Vaccine Consumption Value by Country (2025-2030) & (USD Million)
 Table 62. Asia-Pacific Pneumococcal 13-valent Conjugate Vaccine Sales Quantity by Type (2019-2024) & (K Units)
 Table 63. Asia-Pacific Pneumococcal 13-valent Conjugate Vaccine Sales Quantity by Type (2025-2030) & (K Units)
 Table 64. Asia-Pacific Pneumococcal 13-valent Conjugate Vaccine Sales Quantity by Application (2019-2024) & (K Units)
 Table 65. Asia-Pacific Pneumococcal 13-valent Conjugate Vaccine Sales Quantity by Application (2025-2030) & (K Units)
 Table 66. Asia-Pacific Pneumococcal 13-valent Conjugate Vaccine Sales Quantity by Region (2019-2024) & (K Units)
 Table 67. Asia-Pacific Pneumococcal 13-valent Conjugate Vaccine Sales Quantity by Region (2025-2030) & (K Units)
 Table 68. Asia-Pacific Pneumococcal 13-valent Conjugate Vaccine Consumption Value by Region (2019-2024) & (USD Million)
 Table 69. Asia-Pacific Pneumococcal 13-valent Conjugate Vaccine Consumption Value by Region (2025-2030) & (USD Million)
 Table 70. South America Pneumococcal 13-valent Conjugate Vaccine Sales Quantity by Type (2019-2024) & (K Units)
 Table 71. South America Pneumococcal 13-valent Conjugate Vaccine Sales Quantity by Type (2025-2030) & (K Units)
 Table 72. South America Pneumococcal 13-valent Conjugate Vaccine Sales Quantity by Application (2019-2024) & (K Units)
 Table 73. South America Pneumococcal 13-valent Conjugate Vaccine Sales Quantity by Application (2025-2030) & (K Units)
 Table 74. South America Pneumococcal 13-valent Conjugate Vaccine Sales Quantity by Country (2019-2024) & (K Units)
 Table 75. South America Pneumococcal 13-valent Conjugate Vaccine Sales Quantity by Country (2025-2030) & (K Units)
 Table 76. South America Pneumococcal 13-valent Conjugate Vaccine Consumption Value by Country (2019-2024) & (USD Million)
 Table 77. South America Pneumococcal 13-valent Conjugate Vaccine Consumption Value by Country (2025-2030) & (USD Million)
 Table 78. Middle East & Africa Pneumococcal 13-valent Conjugate Vaccine Sales Quantity by Type (2019-2024) & (K Units)
 Table 79. Middle East & Africa Pneumococcal 13-valent Conjugate Vaccine Sales Quantity by Type (2025-2030) & (K Units)
 Table 80. Middle East & Africa Pneumococcal 13-valent Conjugate Vaccine Sales Quantity by Application (2019-2024) & (K Units)
 Table 81. Middle East & Africa Pneumococcal 13-valent Conjugate Vaccine Sales Quantity by Application (2025-2030) & (K Units)
 Table 82. Middle East & Africa Pneumococcal 13-valent Conjugate Vaccine Sales Quantity by Country (2019-2024) & (K Units)
 Table 83. Middle East & Africa Pneumococcal 13-valent Conjugate Vaccine Sales Quantity by Country (2025-2030) & (K Units)
 Table 84. Middle East & Africa Pneumococcal 13-valent Conjugate Vaccine Consumption Value by Country (2019-2024) & (USD Million)
 Table 85. Middle East & Africa Pneumococcal 13-valent Conjugate Vaccine Consumption Value by Country (2025-2030) & (USD Million)
 Table 86. Pneumococcal 13-valent Conjugate Vaccine Raw Material
 Table 87. Key Manufacturers of Pneumococcal 13-valent Conjugate Vaccine Raw Materials
 Table 88. Pneumococcal 13-valent Conjugate Vaccine Typical Distributors
 Table 89. Pneumococcal 13-valent Conjugate Vaccine Typical Customers


List of Figures
 Figure 1. Pneumococcal 13-valent Conjugate Vaccine Picture
 Figure 2. Global Pneumococcal 13-valent Conjugate Vaccine Revenue by Type, (USD Million), 2019 & 2023 & 2030
 Figure 3. Global Pneumococcal 13-valent Conjugate Vaccine Revenue Market Share by Type in 2023
 Figure 4. 0.5ml Examples
 Figure 5. Other Examples
 Figure 6. Global Pneumococcal 13-valent Conjugate Vaccine Consumption Value by Application, (USD Million), 2019 & 2023 & 2030
 Figure 7. Global Pneumococcal 13-valent Conjugate Vaccine Revenue Market Share by Application in 2023
 Figure 8. Hospital Examples
 Figure 9. Clinic Examples
 Figure 10. Global Pneumococcal 13-valent Conjugate Vaccine Consumption Value, (USD Million): 2019 & 2023 & 2030
 Figure 11. Global Pneumococcal 13-valent Conjugate Vaccine Consumption Value and Forecast (2019-2030) & (USD Million)
 Figure 12. Global Pneumococcal 13-valent Conjugate Vaccine Sales Quantity (2019-2030) & (K Units)
 Figure 13. Global Pneumococcal 13-valent Conjugate Vaccine Price (2019-2030) & (US$/Unit)
 Figure 14. Global Pneumococcal 13-valent Conjugate Vaccine Sales Quantity Market Share by Manufacturer in 2023
 Figure 15. Global Pneumococcal 13-valent Conjugate Vaccine Revenue Market Share by Manufacturer in 2023
 Figure 16. Producer Shipments of Pneumococcal 13-valent Conjugate Vaccine by Manufacturer Sales ($MM) and Market Share (%): 2023
 Figure 17. Top 3 Pneumococcal 13-valent Conjugate Vaccine Manufacturer (Revenue) Market Share in 2023
 Figure 18. Top 6 Pneumococcal 13-valent Conjugate Vaccine Manufacturer (Revenue) Market Share in 2023
 Figure 19. Global Pneumococcal 13-valent Conjugate Vaccine Sales Quantity Market Share by Region (2019-2030)
 Figure 20. Global Pneumococcal 13-valent Conjugate Vaccine Consumption Value Market Share by Region (2019-2030)
 Figure 21. North America Pneumococcal 13-valent Conjugate Vaccine Consumption Value (2019-2030) & (USD Million)
 Figure 22. Europe Pneumococcal 13-valent Conjugate Vaccine Consumption Value (2019-2030) & (USD Million)
 Figure 23. Asia-Pacific Pneumococcal 13-valent Conjugate Vaccine Consumption Value (2019-2030) & (USD Million)
 Figure 24. South America Pneumococcal 13-valent Conjugate Vaccine Consumption Value (2019-2030) & (USD Million)
 Figure 25. Middle East & Africa Pneumococcal 13-valent Conjugate Vaccine Consumption Value (2019-2030) & (USD Million)
 Figure 26. Global Pneumococcal 13-valent Conjugate Vaccine Sales Quantity Market Share by Type (2019-2030)
 Figure 27. Global Pneumococcal 13-valent Conjugate Vaccine Consumption Value Market Share by Type (2019-2030)
 Figure 28. Global Pneumococcal 13-valent Conjugate Vaccine Average Price by Type (2019-2030) & (US$/Unit)
 Figure 29. Global Pneumococcal 13-valent Conjugate Vaccine Sales Quantity Market Share by Application (2019-2030)
 Figure 30. Global Pneumococcal 13-valent Conjugate Vaccine Revenue Market Share by Application (2019-2030)
 Figure 31. Global Pneumococcal 13-valent Conjugate Vaccine Average Price by Application (2019-2030) & (US$/Unit)
 Figure 32. North America Pneumococcal 13-valent Conjugate Vaccine Sales Quantity Market Share by Type (2019-2030)
 Figure 33. North America Pneumococcal 13-valent Conjugate Vaccine Sales Quantity Market Share by Application (2019-2030)
 Figure 34. North America Pneumococcal 13-valent Conjugate Vaccine Sales Quantity Market Share by Country (2019-2030)
 Figure 35. North America Pneumococcal 13-valent Conjugate Vaccine Consumption Value Market Share by Country (2019-2030)
 Figure 36. United States Pneumococcal 13-valent Conjugate Vaccine Consumption Value (2019-2030) & (USD Million)
 Figure 37. Canada Pneumococcal 13-valent Conjugate Vaccine Consumption Value (2019-2030) & (USD Million)
 Figure 38. Mexico Pneumococcal 13-valent Conjugate Vaccine Consumption Value (2019-2030) & (USD Million)
 Figure 39. Europe Pneumococcal 13-valent Conjugate Vaccine Sales Quantity Market Share by Type (2019-2030)
 Figure 40. Europe Pneumococcal 13-valent Conjugate Vaccine Sales Quantity Market Share by Application (2019-2030)
 Figure 41. Europe Pneumococcal 13-valent Conjugate Vaccine Sales Quantity Market Share by Country (2019-2030)
 Figure 42. Europe Pneumococcal 13-valent Conjugate Vaccine Consumption Value Market Share by Country (2019-2030)
 Figure 43. Germany Pneumococcal 13-valent Conjugate Vaccine Consumption Value (2019-2030) & (USD Million)
 Figure 44. France Pneumococcal 13-valent Conjugate Vaccine Consumption Value (2019-2030) & (USD Million)
 Figure 45. United Kingdom Pneumococcal 13-valent Conjugate Vaccine Consumption Value (2019-2030) & (USD Million)
 Figure 46. Russia Pneumococcal 13-valent Conjugate Vaccine Consumption Value (2019-2030) & (USD Million)
 Figure 47. Italy Pneumococcal 13-valent Conjugate Vaccine Consumption Value (2019-2030) & (USD Million)
 Figure 48. Asia-Pacific Pneumococcal 13-valent Conjugate Vaccine Sales Quantity Market Share by Type (2019-2030)
 Figure 49. Asia-Pacific Pneumococcal 13-valent Conjugate Vaccine Sales Quantity Market Share by Application (2019-2030)
 Figure 50. Asia-Pacific Pneumococcal 13-valent Conjugate Vaccine Sales Quantity Market Share by Region (2019-2030)
 Figure 51. Asia-Pacific Pneumococcal 13-valent Conjugate Vaccine Consumption Value Market Share by Region (2019-2030)
 Figure 52. China Pneumococcal 13-valent Conjugate Vaccine Consumption Value (2019-2030) & (USD Million)
 Figure 53. Japan Pneumococcal 13-valent Conjugate Vaccine Consumption Value (2019-2030) & (USD Million)
 Figure 54. South Korea Pneumococcal 13-valent Conjugate Vaccine Consumption Value (2019-2030) & (USD Million)
 Figure 55. India Pneumococcal 13-valent Conjugate Vaccine Consumption Value (2019-2030) & (USD Million)
 Figure 56. Southeast Asia Pneumococcal 13-valent Conjugate Vaccine Consumption Value (2019-2030) & (USD Million)
 Figure 57. Australia Pneumococcal 13-valent Conjugate Vaccine Consumption Value (2019-2030) & (USD Million)
 Figure 58. South America Pneumococcal 13-valent Conjugate Vaccine Sales Quantity Market Share by Type (2019-2030)
 Figure 59. South America Pneumococcal 13-valent Conjugate Vaccine Sales Quantity Market Share by Application (2019-2030)
 Figure 60. South America Pneumococcal 13-valent Conjugate Vaccine Sales Quantity Market Share by Country (2019-2030)
 Figure 61. South America Pneumococcal 13-valent Conjugate Vaccine Consumption Value Market Share by Country (2019-2030)
 Figure 62. Brazil Pneumococcal 13-valent Conjugate Vaccine Consumption Value (2019-2030) & (USD Million)
 Figure 63. Argentina Pneumococcal 13-valent Conjugate Vaccine Consumption Value (2019-2030) & (USD Million)
 Figure 64. Middle East & Africa Pneumococcal 13-valent Conjugate Vaccine Sales Quantity Market Share by Type (2019-2030)
 Figure 65. Middle East & Africa Pneumococcal 13-valent Conjugate Vaccine Sales Quantity Market Share by Application (2019-2030)
 Figure 66. Middle East & Africa Pneumococcal 13-valent Conjugate Vaccine Sales Quantity Market Share by Country (2019-2030)
 Figure 67. Middle East & Africa Pneumococcal 13-valent Conjugate Vaccine Consumption Value Market Share by Country (2019-2030)
 Figure 68. Turkey Pneumococcal 13-valent Conjugate Vaccine Consumption Value (2019-2030) & (USD Million)
 Figure 69. Egypt Pneumococcal 13-valent Conjugate Vaccine Consumption Value (2019-2030) & (USD Million)
 Figure 70. Saudi Arabia Pneumococcal 13-valent Conjugate Vaccine Consumption Value (2019-2030) & (USD Million)
 Figure 71. South Africa Pneumococcal 13-valent Conjugate Vaccine Consumption Value (2019-2030) & (USD Million)
 Figure 72. Pneumococcal 13-valent Conjugate Vaccine Market Drivers
 Figure 73. Pneumococcal 13-valent Conjugate Vaccine Market Restraints
 Figure 74. Pneumococcal 13-valent Conjugate Vaccine Market Trends
 Figure 75. Porters Five Forces Analysis
 Figure 76. Manufacturing Cost Structure Analysis of Pneumococcal 13-valent Conjugate Vaccine in 2023
 Figure 77. Manufacturing Process Analysis of Pneumococcal 13-valent Conjugate Vaccine
 Figure 78. Pneumococcal 13-valent Conjugate Vaccine Industrial Chain
 Figure 79. Sales Channel: Direct to End-User vs Distributors
 Figure 80. Direct Channel Pros & Cons
 Figure 81. Indirect Channel Pros & Cons
 Figure 82. Methodology
 Figure 83. Research Process and Data Source

Research Methodology

Client Requirements

Review and analyze client requirements

Discussion of all the project requirements and queries

Flexibility Check

Project Feasibility Analysis

Finalizing tentative research programme

Structuring project proposal with scope, timeline, and costs

Analyzing Market Dynamics

Determination of key drivers, restraints, challenge, and opportunity

Identifies market needs and trends

Market Size Estimation & Forecast

Estimation of historical data based on secondary and primary data

Anticipating market recast by assigning weightage to market forces (drivers, restraints, opportunities)

Freezing historical and forecast market size estimations based on evolution, trends, outlook, and strategies

Consideration of geography, region-specific product/service demand for region segments

Consideration of product utilization rates, product demand outlook for segments by application or end-user.

Data Source

Secondary Source
Data collections from annual reports, presentations,associations, journals, analyst reports, paid database, press releases, blogs, newsletters,and GIR repositories.

Primary Source
Research discussion with manufacturers, distributors, suppliers, end user, industry experts to verify insights.

Validation and
triangulation of
secondary and primary source.

Collection of data

Cumulating and collating the essential qualitative and quantitative data

Generation of report in client requested format by research analysts

Reviews by expert analysts

Final quality check

Clarifying queries

Receiving feedback

Ensuring satisfaction

01 Identification of data

This step involves identification of several primary and secondary data research sources, including Global Info Research's internal data sources. The primary sources consist of in-depth discussions and interviews with policy makers, industry experts, and data evaluators, whereas secondary sources include a thorough study of market journals, press releases, annual reports, and government and non-government agencies websites.
02 Evaluation of Market Dynamic

This phase includes a detailed evaluation of several factors that are likely to affect the market dynamics. It involves a comprehensive assessment of major market pain points, drivers, and trends. It also comprises a detailed study of research plans and methodology.
03 Collection of Data

This process consists of gathering data, accessing proprietary databases, and reaching out to key industry participants that operate in the market across the value chain. It also involves studying several patterns in the historical data and comparing it with the current scenario.
04 Collaboration of Data

This stage involves the validation of data and arrival at actual statistics, and evolution of the market over the years. It entails the study and analyzes various segments and verticals of the market. An impact analysis is also performed to observe which factors will affect the market in the next few years.
05 Verification and Analysis

This is the final stage, which involves both quantity and quality checks. Although the process of data verification is an integral part of the research process, all data points and statistics and figures are re-checked to uphold their authenticity and validity.

Companies Mentioned

Pfizer
Walvax
BIOKANGTAI

Related Reports

Global Pneumococcal 13-valent Conjugate Vaccine Supply, Demand and Key Producers, 2024-2030

Global Pneumococcal 13-valent Conjugate Vaccine Supply, Demand and Key Producers, 2024-2030

date 28 Oct 2024

date Pharma & Healthcare

The Pneumococcal 13-valent Conjugate Vaccine (PCV13) is a vaccine designed to protect against infections caused by Streptococcus pneumoniae bacteria, commonly known as pneumococcus. It targets 13 specific strains (or serotypes) of the bacteria, which are responsible for severe illnesses such as pneumonia, meningitis, and sepsis. By preventing these infections, PCV13 is particularly important in protecting young children, and people with weakened immune systems.

Product Tags

Pneumococcal 13-valent Conjugate Vaccine

GABA Supplements

L-carnitine Capsule

Opical Thrombin

Purchase Options

Single User License

USD3480.00

Multi User License

USD5220.00

Corporate Users License

USD6960.00

Add To Cart

Buy Now

Popular Product Keywords

AI
semiconductor
electron
5G
artificial intelligence
Battery
new energy
We Provide Professional, Accurate Market Analysis to Help You Stay Ahead of Your Competition.

Speak to our analyst >>
Our Clients
What We Can Provide?

With better results and higher quality products,Our professional reports can achieve four things:
- Insight into the industry market information
- Analyze market development needs
- Prospects for future development
- Develop industry investment strategy
Digging deeper into global industry information and providing market strategies.

Contact Us >>